Soluble Spike Protein
InVivo offers a recombinant form of the Spike protein from severe acute respiratory syndrome-related coronavirus (SARS-CoV-2), Wuhan-Hu-1-isolate (MN908947), which is produced under serum-free conditions in CHO cells (InVivo proprietary optimized; Chinese hamster ovary cells).
Out of stock
Delivery time: Depending on production time
From: 2.500,00 € Excl. VAT and delivery costs
Please contact us for larger quantities.
InVivo offers a recombinant form of the Spike protein from severe acute respiratory syndrome-related coronavirus (SARS-CoV-2), Wuhan-Hu-1-isolate (MN908947), which is produced under serum-free conditions in CHO cells (InVivo proprietary optimized; Chinese hamster ovary cells).
The construct contains the SARS-CoV-2 Spike protein, representing amino acid residues 1 to 1213 of before mentioned annotation. The protein contains a mutated polybasic/ furin cleavage site (682-RRAR-685) to Alanine, and mutations K986P / V987P for stabilization of the protein. The C-terminal transmembrane domain and endodomain were replaced by a thrombin cleavage site, a T4 trimerization site and a C-terminal hexa-His-tag. The recombinant protein is purified using immobilized metal exchange chromatography (IMAC) and preparative SEC (for polishing).
| Product-ID: | Soluble Spike_CHO |
|---|---|
| Expression System: | Mammalian; CHO |
| Protein Acession Number: | GenBank: QHD43416.1 / UniProt: P0DTC2 |
| Amino Acids: | Met1–Pro1213, modified as mentioned above |
| Mature Protein N-Term: | Gln14 (predicted) |
| Tag: | 6 x His-Tag; C-terminal |
| Expected Molecular Weight: | 138 kDa (glycosylated form of Soluble Spike_CHO runs at 100-150 kDa in SDS-Page) |
| Formulation: | Liquid ; 20 mM NaPP, 300 mM NaCl pH 7.2 |
| Concentration: | > 0.5 mg/mL |
The product is for research use or for further manufacturing only.
Additional information
| Document | |
|---|---|
| Notice | The product is for research use or for further manufacturing only. |
You must be logged in to post a review.



Reviews
There are no reviews yet.